Showing results (31-40 of 194) with videos related to
Sort By:
Pageof 20
Cancer Discovery|September 23, 2016
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and ImmunotherapyKlaus Okkenhaug, Mariona Graupera, Bart VanhaesebroeckScientific Reports|September 22, 2018
Vps34/PI3KC3 deletion in kidney proximal tubules impairs apical trafficking and blocks autophagic flux, causing a Fanconi-like syndrome and renal insufficiencyGiuseppina Grieco, Virginie Janssens, Héloïse P Gaide Chevronnay, et al.Current Topics in Microbiology and Immunology|June 16, 2010
PI3K: from the bench to the clinic and backBart Vanhaesebroeck, Peter K Vogt, Christian RommelBritish Journal of Cancer|April 7, 2021
Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approachSarah N Lauder, Bart Vanhaesebroeck, Awen GallimoreJournal of Molecular Medicine (Berlin, Germany)|December 15, 2015
Molecules in medicine mini-review: isoforms of PI3K in biology and diseaseBart Vanhaesebroeck, Maria A Whitehead, Roberto PiñeiroBiochemical and Biophysical Research Communications|July 31, 2002
Human platelets contain p110delta phosphoinositide 3-kinaseJin Zhang, Bart Vanhaesebroeck, Susan E RittenhouseFrontiers in Immunology|December 12, 2024
Lack of phosphatidylinositol 3-kinase VPS34 in regulatory T cells leads to a fatal lymphoproliferative disorder without affecting their developmentChristina J F Courreges, Elizabeth C M Davenport, Benoit Bilanges, et al.Molecular and Cellular Biology|September 17, 2005
Translational deregulation in PDK-1-/- embryonic stem cellsYuichi Tominaga, Tanja Tamgüney, Marina Kolesnichenko, et al.The EMBO Journal|June 22, 2007
The p110delta isoform of PI 3-kinase negatively controls RhoA and PTENEvangelia A Papakonstanti, Anne J Ridley, Bart VanhaesebroeckTrends in Molecular Medicine|September 11, 2018
Cancer-Associated PIK3CA Mutations in Overgrowth DisordersRalitsa R Madsen, Bart Vanhaesebroeck, Robert K SemplePageof 20